Related Experiment Videos
Small-molecule cyclin-dependent kinase modulators
1Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892-4330, USA. sendero@helix.nih.gov
Oncogene
|October 7, 2003
Summary
Targeting cell cycle aberrations with cyclin-dependent kinase (cdk) modulators shows promise for cancer therapy. Clinical trials are evaluating novel small molecules like flavopiridol and UCN-01 for various malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cell cycle progression aberrations are hallmarks of human cancers, primarily involving the retinoblastoma (Rb) pathway.
- Dysfunctional Rb protein, crucial for G(1)/S transition, is frequently observed in neoplasms due to cyclin-dependent kinase (cdk) hyperactivation.
Purpose of the Study:
- To explore the therapeutic potential of small-molecule cdk modulators in cancer prevention and treatment.
- To review the clinical progress and tolerability of direct cdk modulators, including flavopiridol and UCN-01.
Main Methods:
- Review of clinical trial data for direct cdk modulators like flavopiridol, UCN-01, BMS 387032, and R-Roscovitine.
- Analysis of drug administration schedules, efficacy, and toxicity profiles in cancer patients.
Main Results:
- Flavopiridol demonstrated anti-cancer effects including cell cycle arrest, apoptosis, and anti-angiogenesis, with promising survival data in non-small-cell lung cancer.
- UCN-01 exhibits preclinical anti-cancer properties and is being evaluated in various infusion schedules, with dose-limiting toxicities including hyperglycemia.
- Newer agents like BMS 387032 and R-Roscovitine show good tolerability in early-phase trials.
Conclusions:
- Novel small-molecule cdk modulators represent a promising therapeutic strategy for human malignancies.
- Further advanced clinical trials are necessary to establish the efficacy and safety of these agents for cancer therapy and prevention.